LIR Life Sciences Corp.
SKNY
CNSX
| 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -2.86M | -1.99M | -479.90K | -369.40K | -300.60K |
| Total Depreciation and Amortization | 3.70K | 2.80K | 1.80K | 800.00 | -- |
| Total Amortization of Deferred Charges | 2.10K | 241.60K | -- | -- | -- |
| Total Other Non-Cash Items | 1.48M | 500.00K | 0.00 | 100.00 | -- |
| Change in Net Operating Assets | -127.40K | -5.80K | 344.70K | 171.40K | 122.50K |
| Cash from Operations | -1.50M | -1.25M | -133.50K | -197.10K | -178.00K |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 1.12M | 1.05M | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -76.40K | -76.40K | -76.40K | -76.40K | -- |
| Cash from Investing | 1.04M | 972.10K | -76.40K | -76.40K | -- |
| Total Debt Issued | 40.00K | 40.00K | 40.00K | 35.00K | 62.50K |
| Total Debt Repaid | -- | -257.50K | -257.50K | -257.50K | -257.50K |
| Issuance of Common Stock | 1.07M | 1.14M | 1.44M | 377.30K | 377.30K |
| Repurchase of Common Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -3.40K | -8.00K | -8.00K | -8.00K | -8.00K |
| Cash from Financing | 796.00K | 662.20K | 877.20K | 104.20K | 124.30K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | 0.00 | 0.00 |
| Net Change in Cash | 336.20K | 379.60K | 667.10K | -169.40K | -53.70K |